2024 State of Tech in Biopharma Report
AI has the potential to dramatically accelerate scientific progress and bring better medicines to patients faster. What headway has biopharma made in adopting AI and the related technology that enables it? We surveyed 300 biopharma experts to understand investments, readiness, and expected outcomes from AI in an industry undergoing rapid transformation.
Download the 2024 State of Tech in Biopharma Report
Read the full report for more findings on how biopharma is adopting AI and related enabling technology to reach milestones faster.
Methodology & demographics
Benchling designed a survey that was conducted from August 7 to September 10, 2024. Respondents were recruited and screened by a leading third-party research firm and expert network with access to more than 10,000 life sciences professionals. All respondents were employed full-time in the pharmaceuticals and biotechnology industry, based in the U.S. or Europe, and worked in or directly supported one or more of discovery research, process development, analytical development, animal safety and toxicology, or bioanalytical development. The survey included a total sample size of 300 respondents from hundreds of distinct companies. Note that Benchling customers or users may have participated in the survey but were not targeted or specifically recruited.
Respondent demographics included:
- 53% of the respondents represented R&D (including data science), while 47% represented IT, digital, or informatics
- 51% working in the industry for seven or more years
- 58% working at manager level or above
- 42% employed by large companies (1,000+ employees) while 58% employed by small companies (<1,000 employees)
- 59% based in the U.S., and 41% based in Europe
Note: Variations in respondent groups between this year and last year's survey affects the ability to do direct comparisons of results year-on-year.